A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Study of Study Drug JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer
Sponsor: Janssen Research & Development
Enrolling: Male and Female Patients
IRB Number: AAAS0914
U.S. Govt. ID: NCT02609776
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if the study drug, JNJ-61186372, is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC). There are 2 parts of this study. The first part is to determine the dose of JNJ-61186372 that is safe to give to patients with non-small cell lung cancer. The second part of the study is to gather more information about safety and determine if JNJ-61186372 might be effective for your cancer.
This study is closed
Investigator
Catherine Shu, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have confirmed unresectable metastatic non-small cell lung cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE